Eli Lilly's EloraTZP trial results show a 23.3% average weight loss, signaling a potential new benchmark in the company's obesity and type 2 diabetes treatment pipeline.
Positive Phase 2b data showing EloraTZP delivered greater weight loss and A1C reduction than tirzepatide 15 mg alone is likely to strengthen Lilly's obesity and type 2 diabetes franchise.
Eli Lilly's experimental drug EloraTZP outperformed tirzepatide in a 48-week Phase 2b study, demonstrating superior efficacy in weight reduction and glycemic control. Patients achieved an average weight loss of 23.3%, significantly outpacing the 14.8% reduction seen in the tirzepatide cohort.
In the 48-week Phase 2b study, EloraTZP demonstrated superior efficacy, yielding an average weight loss of 23.3% and an A1C reduction of 2.9%, compared to 14.8% and 2.4% respectively for tirzepatide 15 mg.